2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES

This invention concerns the use of a compound of formula (I), a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein Z is hydrogen, halo, C1-6alkyl, Het1, HO-C1-6alkyl-, cyano-C1-6alkyl-, amino-C(=O)-C1-6alkyl-, formylamino-C1...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: MACDONALD, GREGOR JAMES, THURING, JOHANNES WILHELMUS JOHN F, LESAGE, ANNE SIMONE JOSEPHINE, GRANTHAM, CHRISTOPHER JAMES, DINKLO, THEODORUS
Format: Patent
Sprache:eng ; fre
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This invention concerns the use of a compound of formula (I), a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein Z is hydrogen, halo, C1-6alkyl, Het1, HO-C1-6alkyl-, cyano-C1-6alkyl-, amino-C(=O)-C1-6alkyl-, formylamino-C1-6alkyl-, C1-6alkyl-C(=O)-NH-C1-6alkyl-, mono- or di(C1-6alkyl)amino-C(=O)-C1-6alkyl-, phenyl-C1-6alkyl-, or He4-C1-6alkyl-; Q is phenyl, pyridyl, benzofuranyl, 2,3-dihydro-benzofuranyl, pyrazolyl, isoxazolyl or indazolyl wherein each of said ring systems is optionally being substituted with up to three substituents each independently selected from halo, cyano, C1-6alkyl, C1-6alkyl -O-, C1-6alkyl, Ar or polyhaloC1-6alkyl; L is phenyl, pyridyl, pyrimidazolyl, 8-Azapyrimidazolyl, pyridazinyl, imidazothiazolyl or furanyl wherein each of said ring systems may optionally be substituted with one or two or more substituents, each substituent independently being selected from halo, hydroxy, amino, cyano, C1-6alkyl or C1-6alkyl-O-; Het1 represents morpholinyl; pyrazolyl or imidazolyl; Het4 represents morpholinyl, pyrazolyl or imidazolyl; Ar represents phenyl optionally substituted with halo, C1-6alkyl, C1-6alkyl-O- or polyhaloC1-6alkyl; for the manufacture of a medicament for the prevention or the treatment or prophylaxis of psychotic disorders, intellectual impairment disorders or diseases or conditions in which modulation of the .alpha.7 nicotinic receptor is beneficial. Cette invention concerne l'utilisation d'un composé de formule (I), d'un N-oxyde, d'un sel d'addition pharmaceutiquement acceptable, d'une amine quaternaire et d'une forme isomérique stéréochimique desdits éléments. Dans ladite formule, Z est hydrogène, halo, alkyleC1-6, Het1, HO-alkyle C1-6-, cyano-alkyle C1-6-, amino-C(=O)-alkyle C1-6 -, formylamino-alkyle C1-6-, alkyle C1-6 -C(=O)-NH-alkyle C1-6-, mono- ou di(alkyle C1-6)amino-C(=O)-alkyle C1-6-, phényle-alkyle C1-6 -, ou He4-alkyle C1-6-; Q est phényle, pyridyle, benzofuranyle, 2,3-dihydro-benzofuranyle, pyrazolyle, isoxazolyle ou indazolyle, chacun desdits systèmes cycliques étant éventuellement substitué par des substituants dont le nombre peut aller jusqu'à trois, chaque substituant étant choisi indépendamment dans le groupe constitué par halo, cyano, alkyle C1-6, alkyle C1-6-O-, alkyle C1-6, Ar ou polyhalo-alkyle C1-6; L est phényle, pyridyle, pyrimidazolyle, 8-azapyrimidazolyle, pyridazinyle, imidazothiazolyle ou furanyle, chacun desdits systè